Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KIT positive |
Therapy | Imatinib |
Indication/Tumor Type | germ cell cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT positive | germ cell cancer | no benefit | Imatinib | Phase II | Actionable | In a small Phase II study, 6 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496). | 16462496 |
PubMed Id | Reference Title | Details |
---|---|---|
(16462496) | Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. | Full reference... |